Brief: Lisata Therapeutics And Catalent Announce Global Antibody-Drug Conjugate License Agreement
08/10/2025 14:01
Oct 8 (Reuters) - Lisata Therapeutics Inc LSTA.O: LISATA THERAPEUTICS AND CATALENT ANNOUNCE GLOBAL ANTIBODY-DRUG CONJUGATE (ADC) LICENSE AGREEMENT LISATA THERAPEUTICS INC - TO RECEIVE OVER $10 MILLION IN MILESTONE PAYMENTS Source text: ID:nGNX8lvgcF Further company coverage: LSTA.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lisata Therapeutics
See all newsBrief: Lisata Therapeutics Appoints Jeff Farrow To Board Of Directors
Brief: Lisata Therapeutics Announces New Method Of Use Patent Granted For Certepetide In The Treatment Of Pancreatic Cancer And Other Solid Tumors
NASDAQ RESUMED AT 09:55 AM
NASDAQ TRADE HALT HALT NEWS PENDING AT 07:55 AM
U.S. STOCKS ON THE MOVE -Expeditors International, Waters, Ameresco